Identification and Quantification of Transient Receptor Potential Vanilloid 1 (TRPV1) in Equine Articular Tissue.
Authors: Braucke Anne Franck Gallagher Vom, Frederiksen Nanna Lysemose, Berg Lise Charlotte, Aarsvold Stacie, Müller Felix Christoph, Boesen Mikael Ploug, Lindegaard Casper
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary: TRPV1 in Equine Joint Disease TRPV1 represents a promising therapeutic target for equine joint pain and osteoarthritis, yet its presence and behaviour in equine articular tissue had not been systematically characterised. Researchers examined synovial tissue from 15 horses' metacarpo/metatarsophalangeal joints, stratified as healthy or pathological based on synovial fluid analysis, macroscopic assessment, and MRI findings, using ELISA and quantitative real-time PCR to quantify TRPV1 protein and mRNA expression respectively. TRPV1 protein concentration was significantly elevated in pathological joints (12.9 × 10⁻⁷ ng/mL) compared to healthy joints (8.4 × 10⁻⁷ ng/mL, p = 0.01), suggesting upregulation during joint disease, though mRNA expression levels showed no statistical difference between groups. These findings provide evidence that TRPV1 could be exploited therapeutically, particularly given the receptor's established role in pain signalling and inflammation in other tissues—a departure from current management approaches that largely address symptoms rather than disease modification. Whilst inflammatory markers (IL-6 and TNF-α) remained notably low in both cohorts, the protein-level upregulation of TRPV1 in pathological joints warrants further investigation into selective TRPV1 antagonism as a disease-modifying treatment strategy for equine joint pain.
Read the full abstract on PubMed
Practical Takeaways
- •TRPV1 receptors are present and upregulated in inflamed equine joints, suggesting they may be a viable therapeutic target for managing joint pain and osteoarthritis in horses
- •Current findings are exploratory; do not yet inform treatment decisions, but future TRPV1-targeted therapies could offer disease-modifying approaches rather than just symptomatic relief for lameness
- •More research is needed to understand the clinical significance and translate these molecular findings into practical interventions for equine joint disease
Key Findings
- •TRPV1 receptor was detected in all 15 equine metacarpo/metatarsophalangeal joints at both mRNA and protein levels
- •TRPV1 protein concentration was significantly higher in joints with pathology (12.9 × 10⁻⁷ ng/mL) compared to healthy joints (8.4 × 10⁻⁷ ng/mL; p = 0.01)
- •TRPV1 mRNA expression showed a trend toward higher levels in pathological joints (0.24 vs 0.16) but this difference was not statistically significant (p = 0.43)
- •IL-6 and TNF-α mRNA expression was very low in both healthy and pathological joint samples